Publicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (16)

2023

  1. Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study—The U-SEX-2 GESIDA 9416 Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2022

  1. A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid

    Communications Medicine, Vol. 2, Núm. 1

2021

  1. Different HCV exposure drives specific miRNA profile in PBMCS of HIV patients

    Biomedicines, Vol. 9, Núm. 11

2020

  1. Hepatitis C virus influences HIV-1 viral splicing in coinfected patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-18

  2. Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility after Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016

    Open Forum Infectious Diseases, Vol. 7, Núm. 12

2019

  1. Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIda 9416 study

    PLoS ONE, Vol. 14, Núm. 12

  2. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

2018

  1. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real-world practice: Madrid coinfection registry findings

    Hepatology, Vol. 68, Núm. 1, pp. 32-47

  2. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals

    Journal of Viral Hepatitis, Vol. 25, Núm. 7, pp. 818-824

2017

  1. Epidemiology and prognosis of candidaemia in elderly patients

    Mycoses, Vol. 60, Núm. 12, pp. 808-817

  2. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

  3. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

2016

  1. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8

2015

  1. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9

  2. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

    Journal of Infection, Vol. 71, Núm. 3, pp. 385-394

  3. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 21, Núm. 5, pp. 491.e1-491.e10